


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A ~~compound~~ compound of the formula:



or the pharmaceutically acceptable acid salts thereof wherein:


R<sub>1</sub> is halogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>2</sub> and R<sub>3</sub> are the same or different and represent hydrogen, halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino, with the proviso that R<sub>2</sub> and R<sub>3</sub> may not be 2-isopropoxyl and hydrogen respectively when R<sub>1</sub> is bromo;

wherein in an assay for D2 receptor binding the compound exhibits a K<sub>i</sub> value of greater than 300 nM.

2. (Original) A compound according to Claim 1, wherein R<sub>1</sub> is methyl.

3. (Currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

R<sub>x</sub> is fluorine, chlorine, bromine, or iodine; and


R<sub>2</sub> and R<sub>3</sub> are the same or different and represent hydrogen, halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D2 receptor binding the compound exhibits a K<sub>i</sub> value of greater than 300 nM.


4. (Original) A compound according to Claim 3, wherein R<sub>2</sub> and R<sub>3</sub> may not be 2-isopropoxyl and hydrogen, respectively, when R<sub>1</sub> is bromo.

5. (Original) A compound according to claim 3, wherein R<sub>x</sub> is chloride; R<sub>2</sub> and R<sub>3</sub> may not be 2-isopropoxyl and hydrogen, respectively, when R<sub>1</sub> is bromo; R<sub>2</sub> is chloride, methyl or methoxy; and R<sub>3</sub> is hydrogen or methyl.

6. (Original) A compound according to claim 5, wherein the phenyl group substituted with R<sub>2</sub> and R<sub>3</sub> is selected from the group consisting of:



7. (Currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein

$R_a$  is  $C_1$ - $C_4$  alkyl; and


$R_2$  and  $R_3$  are the same or different and represent hydrogen, halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, alkylthio, hydroxy, amino, monoalkylamino or dialkylamino;

wherein in an assay for D2 receptor binding the compound exhibits a  $K_i$  value of greater than 300 nM.


8. (Original) A compound according to Claim 7, wherein  $R_1$  is methyl.

9. (Original) A compound of according to Claim 7, wherein  $R_2$  is chloride, fluoride, methyl or methoxy; and  $R_3$  is hydrogen or methyl.

10. (Original) A compound according to claim 8, wherein the phenyl group substituted with  $R_2$  and  $R_3$  is selected from the group consisting of:



11. (Currently amended) A compound of the formula:



or the pharmaceutically acceptable salts thereof wherein:

R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl or halogen; and

wherein in an assay for D2 receptor binding the compound  
exhibits a K<sub>i</sub> value of greater than 300 nM.

12. (Original) A compound according to Claim 11, wherein R<sub>1</sub> is chloro.

13-35. (Canceled)